Interchangeability of conjugated Haemophilus influenzae type b vaccines during primary immunisation of infants
- 30 March 1996
- Vol. 312 (7034) , 817-818
- https://doi.org/10.1136/bmj.312.7034.817
Abstract
The introduction of conjugate Haemophilus influenzae type b vaccines into the primary infant immunisation schedule in October 1992 has resulted in a dramatic decline in the incidence of infection with invasive Haemophilus influenzae type b in Britain.1 Two different formulations of the conjugate vaccines are licensed in the United Kingdom for administration at 2, 3, and 4 months of age. Because of the lack of data about the safety and immunogenicity of the vaccines when the conjugates are interchanged during primary immunisation, the Department of Health advises against this2 and purchases one formulation for routine use. Reliance on a single supplier for a national immunisation programme is unsatisfactory, and, in the absence of contraindications, the ability to interchange vaccines of different conjugates is highly desirable. We report the effect on immunogenicity and reactogenicity of interchanging the two different Haemophilus influenzae type b conjugate vaccines during …Keywords
This publication has 4 references indexed in Scilit:
- Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-TThe Lancet, 1994
- Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infantsThe Journal of Pediatrics, 1992
- Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation schedule.Archives of Disease in Childhood, 1992
- The Protective Level of Serum Antibodies to the Capsular Polysaccharide of Haemophilus influenzae Type bThe Journal of Infectious Diseases, 1983